Levothyroxine Is No More For Lannett: Here’s How The Company Aims To Replace It

 
• By Dean Rudge
ManOnCliff
Lannett is attempting to bridge the gap left by Amneal snapping up distribution rights to levothyroxine • Source: Shutterstock

More from Strategy

More from Business